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Valrubicin in a Topical Formulation Treats Psoriasis in
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Cecilia Rosada1, Karin Stenderup1, Elisabeth de Darko´2, Frederik Dagnaes-Hansen3, Søren Kamp4 and
Tomas Norman Dam4
Valrubicin is a cytostatic drug currently approved by the American Federal Drug Administration as a
trademarked Valstar sterile solution for the treatment of bladder cancer. Valrubicin has shown an excellent
therapeutic potential with minimal toxicity. This study investigated the effect in vivo of treating psoriasis with a
daily topical application of valrubicin cream in a psoriasis xenograft transplantation model. Psoriasis is
characterized by an accelerated keratinocyte proliferation, resulting in increased epidermal thickness. We thus
studied the cytostatic potential of valrubicin on epidermal keratinocytes. In vivo, valrubicin treatment resulted
in a normalization of epidermal morphology and a reduction in epidermal thickness after 12 days. In addition,
the dermal vessel pattern was reduced and the stratum granulosum was regained. Staining for a regenerative
proliferation marker showed a decrease in keratinocyte proliferation, and scattered epidermal cells showed
apoptosis. In vitro, valrubicin was shown to localize solely to the cell cytoplasm in cultured keratinocytes and to
reduce keratinocyte proliferation as well as increase apoptosis by activation of caspases 3, 7, and 9. Our results
indicated that valrubicin successfully treats psoriasis in a xenograft transplantation model, suggesting that
topical valrubicin may become an upcoming treatment for psoriasis.
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INTRODUCTION
Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a sec-
ond-generation anthracycline: a cell cytostatic drug derived
from the highly effective anthracycline doxorubicin (Adria-
mycin) (Israel et al., 1975; Krishan et al., 1981). Anthracy-
clines have been known since the 1960s and are accepted
as antitumoral drugs because of their cytostatic effect
(Bonadonna et al., 1969; Di Marco et al., 1969). Chemother-
apeutic drugs are very effective molecules; however, they are
often associated with severe side effects including severe
toxicity to skin and tissues (Israel et al., 1975; Dantchev et al.,
1980, 1984). As their clinical superiority is compromised by
dose-limiting severe side effects, extensive efforts have been
made to develop anthracycline derivatives or analogs with an
improved efficacy and safety profile (Krishan et al., 1981;
Lothstein et al., 1998, 2001; Minotti et al., 2004). Valrubicin
was a result of such molecular structural modifications (Israel
et al., 1975; Dantchev et al., 1980, 1984; Masquelier et al.,
1986). It is highly lipophilic, is located in the cytoplasm,
and shows no binding to DNA (Burke et al., 1989, 1990;
Lothstein et al., 2001). The absence of skin irritation and skin
toxicity as ulceration and necrosis, which is unique among
anthracyclines, in combination with the negligible systemic
absorption on repeated dermal application, makes valrubicin
relevant for the treatment of hyperproliferative debilitating
but not life-threatening disease (Sweatman et al., 1991;
Patterson et al., 2000; Steinberg et al., 2000; Wani et al.,
2000). Thus, valrubicin constitutes a potential drug in benign
hyperproliferative diseases such as psoriasis. In the cell
cytoplasm, valrubicin interacts with protein kinase C (PKC)
affecting the PKC signal-transduction pathway, resulting in
the regulation of keratinocyte proliferation and maturation. In
plasma, valrubicin is quickly metabolized into the active
metabolite AD41 (N-trifluoroacetyladriamycin), which loca-
lizes to the cell nucleus and interacts with nuclear DNA
topoisomerases, affecting cell proliferation and survival
(Chuang et al., 1992; Wani et al., 2000). Since its
introduction in 1998, valrubicin has been used in bladder
cancer therapy (Greenberg et al., 1997; Steinberg et al.,
2000). The antitumorigenic activity was achieved by contact
with the bladder wall and subsequent absorption by cancer
cells, in which valrubicin expressed its cytostatic effect,
resulting in a reduced proliferation of tumoral cells (Steinberg
et al., 2000; Wani et al., 2000). A reduction in cell
proliferation on valrubicin exposure has been shown
in vitro in many cell types, such as epithelial bladder cancer
cells, lymphoblasts, fibroblasts, leukemia cells, and macro-
phages (Krishan et al., 1976; Facchinetti et al., 1978;
Schwartz and Kanter, 1981; Niell et al., 1987). However, to
our knowledge, its effect on keratinocytes has not been
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shown. Hyperproliferating keratinocytes resulting in an
increased epidermal thickness is a characteristic of psoriasis
(Bowcock and Krueger, 2005); thus, a drug able to reduce
such hyperproliferation would add to the number of possible
treatments for psoriasis. Remission of psoriasis has previously
been reported during a systemic treatment of cancer patients
with anthracyclines (Pisano et al., 2004). This study
investigated the possibility of using valrubicin as a cream
for topical use by employing the psoriasis xenograft
transplantation model in which psoriatic skin is transplanted
onto immune-deficient mice (Dam et al., 1999). The grafted
psoriatic skin was topically treated with valrubicin once daily
for 12 days and the psoriasis phenotype was observed
clinically and given a semiquantitative psoriasis score. After
treatment, epidermal thickness from graft biopsies was
measured and used as an end point for psoriasis severity.
Valrubicin alleviated the symptoms of psoriasis in vivo and
also influenced proliferation and apoptosis both in vitro and
in vivo, suggesting that valrubicin cream would be valuable
in an upcoming treatment of psoriasis.
RESULTS
Valrubicin induces psoriasis remission
In the psoriasis xenograft transplantation model, human
psoriasis plaque skin was transplanted onto SCID (severe
combined immunodeficient) mice maintaining the character-
istics of psoriasis. Mice grafted with psoriatic plaque skin
were divided into four treatment groups: valrubicin cream,
vehicle cream, untreated, and clobetasol propionate (a group
IV corticosteroid approved as topical treatment for psoriasis).
The vehicle cream group was compared with the untreated
group to establish the inertia of this newly formulated vehicle
cream on psoriasis. All treatments were applied once daily to
the human grafted skin in the psoriasis xenograft transplanta-
tion model for 12 days and all grafts were evaluated every
third day by a semiquantitative clinical psoriasis score.
The semiquantitative clinical psoriasis score was signifi-
cantly reduced in the valrubicin group (1.7±0.1; mean±
SEM, Po0.01) compared with that in the vehicle group
(2.2±0.1; mean±SEM), indicating remission of psoriasis
(Figure 1a). Similarly, the semiquantitative clinical psoriasis
score in the clobetasol propionate-treated group was reduced
to 1.5±0.1 (mean±SEM) (Figure 1a). From the observations
of the psoriatic graft, no significant difference was found
between vehicle cream-treated and untreated skin in both
semiquantitative clinical psoriasis scores (Figure 1b).
Psoriasis resolution was corroborated by measures of
epidermal thickness. Valrubicin decreased epidermal thick-
ness to 238±28 mm (mean±SEM, Po0.01) from
489±49 mm (mean±SEM) in the vehicle group (Figure 1c).
A microscopic observation of valrubicin-treated skin showed
a partial normalization of psoriatic morphology and papillo-
matosis; the stratum granulosum reappeared and paraker-
atosis was greatly diminished. The clobetasol propionate-
treated group showed a reduction to 100±30 mm (mean±
SEM); not surprisingly, variable grades of tissue atrophy were
additionally observed in this group. No significant difference
was found between vehicle cream-treated and untreated skin
in the measures of epidermal thickness (Figure 1d). Repre-
sentative tissue sections from each treatment group are
shown in Figure 1e.
In general, mice were not affected by vehicle or valrubicin
treatment, as indicated by a weight gain throughout the
experiment; in contrast, the clobetasol propionate-treated
mice lost weight during the 12-day study period, indicating a
less well-being of these animals. To test for systemic effect,
post-treatment blood samples were taken and analyzed for
the presence of valrubicin or AD41, or for doxorubicin (as
metabolic product). No drugs were detected (data not
shown).
Cellular uptake of valrubicin in keratinocytes
The in vivo data showed a thinning of the epidermal layer
that prompted us to investigate further the cellular uptake
of valrubicin in keratinocytes. The spontaneously transformed
normal human keratinocyte cell line HaCaT was therefore
cultured in the presence or absence of valrubicin, AD41,
and doxorubicin. After 10minutes, doxorubicin localized
into the cell nucleus, valrubicin entered the cell but seemed
to localize in the cytoplasm without entering the nucleus,
and AD41 was evenly distributed in both the cytoplasm
and the nucleus. The distribution patterns observed for all
three drugs after 10minutes were similar to those observed at
later time points. Representative pictures of cellular uptake of
valrubicin, AD41, and doxorubicin at 10minutes and 2 hours
are shown in Figure 2a–f. In addition, in vivo skin penetration
of valrubicin in the new cream formulation has been assessed
using a Franz diffusion cell (Kligman and Christophers, 1963),
in which valrubicin was shown to penetrate perturbed skin
but not intact skin (unpublished data).
Valrubicin decreases keratinocyte proliferation in vitro and
in vivo
The in vivo results showed that valrubicin was able to
ameliorate psoriasis and in vitro data showed that valrubicin
entered the keratinocytes and localized to the cytoplasm.
We then investigated whether the effect seen in vivo was
possibly because of an action of valrubicin on keratinocyte
proliferation.
HaCaT cell cultures were incubated with valrubicin,
AD41, and doxorubicin in increasing concentrations; valru-
bicin, AD41, and doxorubicin dose dependently decreased
the proliferation of HaCaT cells at 48 hours after stimulation
(Figure 3a). Doxorubicin was most effective in decreasing
proliferation and reduced proliferation B30% more effi-
ciently than did valrubicin at concentrations X0.05 mgml1.
AD41 required higher doses to achieve the same decrease in
proliferation compared with valrubicin.
Furthermore, the effect of valrubicin was investigated in
three distinct cultures of primary keratinocytes. Proliferation
curves are shown at 48 hours (Figure 3b) and valrubicin was
shown to decrease proliferation in a manner similar to HaCaT
cells. Discrepancies were found among keratinocytes from
distinct donors mirroring interdonor variation.
To explore the effect of valrubicin on proliferation in vivo,
sections from transplanted and treated psoriatic plaque skin
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grafts were stained for keratin (K) 16, a marker of keratinocyte
regenerative proliferation. As expected, the vehicle
(Figure 3c) as well as untreated (data not shown) psoriatic
grafts expressed K16 throughout the epidermis. Valrubicin
(Figure 3d) only displayed the expression of K16 in the most
superficial layers of the epidermis, similar to clobetasol
propionate (Figure 3e). This expression pattern agrees with
the observed thinning of the epidermis (Figure 1e). The K16
expression pattern from a nonlesional skin biopsy is shown
for comparison (Figure 3f).
Valrubicin induces apoptosis in keratinocytes in vitro and
in vivo
Apoptosis on keratinocytes may also contribute toward
explaining the epidermal thinning that we observed in vivo.
Thus, we explored the effect of valrubicin in inducing
apoptosis. We used the characteristics of apoptotic cells in
translocating phosphatidylserine from the inner to the outer
leaflet of the cytoplasmic membrane to identify apoptotic
cells in valrubicin-, AD41-, and doxorubicin-treated cell
cultures by staining with the human vascular anticoagulant
annexin V. Several cells were observed to stain positive with
annexin V and negative with SYTOX (detecting necrosis),
thus confirming the induction of apoptosis in HaCaT cells
cultured for 10minutes with valrubicin (Figure 4b), AD41
(Figure 4c), or doxorubicin (Figure 4d). In the vehicle-treated
control cultures, only few or no cells were stained (Figure 4a);
this was also true after 30minutes of stimulation (data not
shown). Apparently, doxorubicin was the most effective in
inducing apoptosis in HaCaT cells after exposure for
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Figure 1. Topical application of valrubicin promotes remission of psoriasis. Psoriatic plaque skin biopsies were transplanted onto SCID mice in the
psoriasis xenograft transplantation model. During treatment, semiquantitative clinical psoriasis scores were determined every third day for 12 days (a, b). After
treatment, the mice were killed and biopsies were taken, paraffin embedded, and stained with H&E. Epidermal thickness was measured on H&E-stained sections
(c, d). Valrubicin induced resolution in psoriasis (a, c, and e). Grafted mice were divided into three groups: vehicle (’, n¼ 10)-, valrubicin (’, n¼ 12)-, and
clobetasol propionate (&, n¼11)-treated. Valrubicin significantly decreased the semiquantitative clinical psoriasis score (a, *Po0.01; scores represent
mean±SEM) and epidermal thickness (c, *Po0.01, columns indicate meanþ SEM) as compared with vehicle. Vehicle cream treatment showed no effect on
psoriasis (b, d). Grafted mice were divided into two groups: one treated with vehicle (’, n¼ 10) and the other left untreated (&, n¼9). Treatment with vehicle
showed no significant effect on the semiquantitative clinical psoriasis score (b, scores represent mean±SEM) or on epidermal thickness (d, columns indicate
meanþ SEM). Representative tissue samples of each treatment group are shown (e). Bar¼100 mm.
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10minutes, but after 30minutes, valrubicin and AD41
showed a similar activation of programmed cell death (data
not shown).
A following event of apoptosis is the induction of caspases,
in which caspase 9 is activated before caspases 3 and 7. The
activation of these caspases in HaCaT cells was measured at
24 and 48 hours after treatment with valrubicin, AD41, and
doxorubicin, at concentrations chosen from dose–response
curves at 48 hours; these doses induced a proliferation
reduction of 5, 1, and 30%, respectively (Figure 4e,f). After
24 hours, doxorubicin activated caspase 9 and caspases 3
and 7 approximately two- and sixfold, respectively, com-
pared with vehicle-treated cultures (Figure 4e), and after
48 hours, the induced activations were no longer apparent
(Figure 4f). Valrubicin and AD41 did not seem to activate
these caspases by stimulation for 24 hours (Figure 4f), but
after 48 hours, caspases 3 and 7 were activated approxi-
mately four- and fivefold, respectively, and caspase 9
approximately twofold for both drugs (Figure 4g).
Apoptosis in vivo was studied by staining for a specific
cleavage of cytokeratin 18, a specific marker of early apop-
tosis. Scattered epidermal cells underwent apoptosis in the
Valrubicin
AD41
Doxorubicin
2 hours10 minutes
Figure 2. The cellular uptake of valrubicin in keratinocytes. HaCaT cells
were cultured in the presence or absence of valrubicin (a, b), AD41 (c, d), and
doxorubicin (e, f) for 10minutes (a, c, and e) and 2 hours (b, d, and f). At the
time indicated, the cells were washed in PBS and left to air-dry. Valrubicin
seemed to localize to the cytoplasm without entering the nucleus, AD41
seemed to be evenly distributed in both the cytoplasm and the nucleus, and
doxorubicin into the cell nucleus. Pictures were taken using a confocal
microscope at 580 nm. Bar¼ 16mm.
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Figure 3. Valrubicin decreases keratinocyte proliferation in vitro and in vivo.
In vitro, HaCaT cells were cultured for 48hours in the presence of valrubicin,
AD41, and doxorubicin in increasing concentrations as indicated (a).
Keratinocytes from three different donors were cultured for 48hours in the
presence of increasing concentrations of valrubicin as indicated (b). As control,
similar cultures were set up with vehicle stimulation. Percentage proliferation is
the estimated number of cells in the stimulated cultures versus control. Valrubicin
decreased keratinocyte proliferation in cells from all donors; discrepancies are
attributed to interdonor variation (b). In HaCaT cells, doxorubicin decreased cell
proliferation more extensively than did valrubicin when used at the same
concentration. AD41 required a higher concentration to achieve a similar
decrease in proliferation compared with valrubicin. In vivo, sections from
transplanted and treated psoriatic plaque skin biopsies were stained for keratin 16
to evaluate the proliferation of keratinocytes. Representative sections stained for
keratin 16 from grafts treated with vehicle cream (c), valrubicin (d), and clobetasol
propionate (e) are shown, together with a nonlesional psoriatic skin biopsy (f).
Valrubicin and clobetasol propionate seemed to decrease the amount of
expressed keratin 16 compared with vehicle treatment. Bar¼ 100mm.
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valrubicin-treated group, whereas no cells stained positive in
the vehicle group (Figure 4g and h).
DISCUSSION
This study addressed the effect of a known anthracycline—
valrubicin—in ameliorating psoriasis. It is accepted that the
pathology of psoriasis has a keratinocyte, an immune cell,
and a genetic component. New knowledge regarding this
disease is evolving by the quest for finding an optimal
treatment. In the last few decades, focus has been on the role
of tumor necrosis factor-a, and several biologics have been
developed to control this cytokine and thus reduce psoriasis
relapses (Warren et al., 2009). On the other hand, new
interest has been generated in the Th-17 type of immune
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Figure 4. Valrubicin induces apoptosis in keratinocytes in vitro and in vivo. HaCaT cells were cultured in the presence or absence of valrubicin (b), AD41 (c),
and doxorubicin (d) for 10minutes. Cells were stained with annexin V to visualize the translocation of phosphatidylserine. Positively stained cells were seen for
all treatments but not in the untreated control (a). Bar¼100 mm (a) and bar¼ 25mm (b–d). HaCaT cells were as well cultured for 24 (e) and 48 hours (f) in the
presence of valrubicin (0.05 mgml1), AD41 (0.5 mgml1), and doxorubicin (0.05mgml1). As control, similar cultures were set up with vehicle stimulation.
Caspase 3/7 and caspase 9 activations were measured in relative luminescence units and the percentage of activation was displayed as treated vs. control.
Doxorubicin activated all three caspases after 24 hours and valrubicin and AD41 after 48 hours. In vivo, sections from transplanted and treated psoriatic plaque
skin biopsies were stained for caspase-cleaved cytokeratin 18 (M30 CytoDEATH antibody) to evaluate apoptosis in valrubicin-treated skin. Representative
sections from grafts treated with vehicle cream (g) and valrubicin (h) are shown. The brown precipitate highlights the apoptotic cells of the epidermis.
Bar¼25 mm.
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response, whereas the genetic component in the form of
recurrent mutated gene loci is still under loop (Fitch et al.,
2007; Duffin et al., 2008; Kryczek et al., 2008; Duffin and
Krueger, 2009). Very recently, the psoriatic keratinocyte has
returned to an investigative status with regard to the
expression pattern of PKC subtypes (Denning, 2004).
Irrespective of the aspect of psoriasis investigated, it is
accepted that the hyperproliferation of keratinocytes is
responsible for increased epidermal thickness, thus the
characteristic scaling of skin in a psoriatic patient. A
reduction in this hyperproliferation by a cytostatic drug
would lead to a remission of psoriasis.
We showed that valrubicin has the potential to induce
remission of psoriasis in a xenograft transplantation model. It
penetrated the cells and reduced proliferation and induced
apoptosis in keratinocytes.
We used a psoriasis xenograft transplantation model in
which human psoriatic skin is transplanted onto the back of
SCID mice. Valrubicin cream was effective in inducing
remission of psoriasis on a single application daily for 12
days, whereas vehicle-treated skin showed no sign of
improvement. Besides clinical improvement, epidermal
thickness was reduced by 50%. This reduction was compar-
able with the effective injection of cyclosporin A, a well-
known positive control in this model (Dam et al., 1999;
Stenderup et al., 2009). As valrubicin is a naturally
fluorescent drug, it could be suspected that the observed
remission of psoriasis may be because of a photosensitizing
effect; however, no epidermis phototoxicity has been
ascribed to valrubicin (unpublished result).
Valrubicin effect was assessed in comparison with
clobetasol propionate, a well-known topical treatment for
psoriasis. Signs of atrophy of the skin and subcutaneous
tissues and a reduced general well-being were observed in
clobetasol propionate-treated animals; in addition, this group
showed a distinct reduction in body weight. These symptoms
were absent in valrubicin- or vehicle-treated animals. To
investigate a possible systemic effect of valrubicin, blood
samples from mice in the valrubicin group were taken
and no presence of the drug or its metabolites was detected.
The lack of systemic toxicity for valrubicin observed in
this study was in accordance with previous studies on
bladder cell wall absorption, in which a limited systemic
absorption of this drug was shown (Greenberg et al., 1997;
Patterson et al., 2000). To investigate the manner by which
cell proliferation was affected by valrubicin, we first showed
that valrubicin, AD41, and doxorubicin were all able to
penetrate the keratinocyte cytoplasmic membrane and to
localize within the cell. Valrubicin accumulated in the
cytoplasm as described in other cell types (Wani et al.,
2000) and doxorubicin accumulated in the cell nucleus.
AD41 was found both in the cytoplasm and in the nucleus.
The presence of AD41 in the nucleus was expected, as it
correlates with the description that AD41 explicates its effect
through intercalation with topoisomerases (Bodley et al.,
1989). The different localization of valrubicin and doxor-
ubicin suggests that these molecules influence cell metabo-
lism in distinct ways.
We then investigated whether these drugs had an effect on
proliferation. In vitro, we showed that valrubicin reduced the
proliferation of HaCaT cells in culture in a dose-dependent
manner; this was confirmed in primary keratinocytes. Its
metabolite, AD41, was also effective in HaCaT cells;
however, higher doses were needed to obtain a similar
influence. Whether the effect of valrubicin was partially due
to intracellular metabolism and conversion into its main
metabolite, AD41, cannot be excluded. Doxorubicin was the
most effective drug in reducing proliferation, and has been
described previously to be 10 times more potent than
valrubicin (Onrust and Lamb, 1999).
In vivo, valrubicin reduced the proliferation of psoriatic
skin, as shown by the reduction in K16 staining of histological
sections. K16 is a marker for regenerative proliferation
present, for instance, in psoriatic and wound repair areas.
In several cell types, valrubicin has been described to
affect proliferation (Chuang et al., 1983; Bodley et al., 1989;
Wani et al., 2000); however, in keratinocytes, it seemed to be
more effective. It is appealing to suggest that the reason for
the increased effect in keratinocytes resides in cell type
differences of downstream cellular signaling. Valrubicin is
described to interact with PKC in the cytoplasm, and PKC has
a major role in the regulation of keratinocyte proliferation
and differentiation (Raj et al., 2006). Several PKCs seem to be
differently activated or inhibited at diverse stages of
keratinocyte maturation (Denning, 2004); for instance,
PKC-z seems to be overexpressed in psoriatic skin (Zhao
et al., 2008). Whether valrubicin influences keratinocyte
proliferation alone or affects immune cell signaling as well is
yet to be investigated. A regulation of T cells by valrubicin
can be expected in light of recent data showing psoriasis
amelioration by oral administration of a PKC inhibitor (Skvara
et al., 2008). The manner in which valrubicin inhibits or
promotes the activity of different PKC family members
affecting both proliferation and differentiation of keratino-
cytes and immune cells warrants further investigation
(Chuang et al., 1992; Wani et al., 2000; Denning, 2004).
The reduction in epidermal thickness associated with a
reduced proliferation of keratinocytes can additionally be
explained by an induction of apoptosis. Therefore, we
investigated in vitro whether valrubicin could induce
apoptosis in a HaCaT cell culture. One of the early events
in apoptosis is the flipping of phosphatidylserine from the
inner layer of the cytoplasmic membrane to the outer leaflet
while keeping the membrane itself intact. All drugs were able
to initiate such a process within 10minutes from exposure.
Moreover, valrubicin, AD41, and doxorubicin were able to
induce the activation of caspase 9, an initiator caspase, and
of caspases 3 and 7, known as effector caspases. Valrubicin
and AD41 seem to require a longer time to induce apoptosis
than doxorubicin. Apoptosis seems to peak at 24 hours of
exposure for doxorubicin, whereas valrubicin- and AD41-
induced apoptosis is evident after 48 hours. At this time point,
doxorubicin seems to have induced maximal cell death. This
finding corroborates the clinical observations of doxorubicin-
induced necrosis of tissues, making this drug unsuitable for
topical use. In vivo, the psoriatic skin treated with valrubicin
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presented signs of apoptosis in situ as shown by a staining of
biopsies with an antibody recognizing a caspase cleavage site
on cytokeratin 18, a defined early apoptotic event. Taken
together, these data corroborate the hypothesis that valrubi-
cin explicates its effect on psoriatic skin partially by
activating apoptotic signals in keratinocytes.
PKC also has a role in apoptosis in keratinocytes; thus, it is
expected that valrubicin through this interaction would
regulate apoptosis; an analog of valrubicin, also presenting
a valerate moiety in its structure, has been shown to induce
apoptosis by activating PKC-d, followed by calcium efflux
from the mitochondria (Barrett et al., 2002).
In conclusion, topically applied valrubicin was effective in
inducing remission of psoriasis in vivo in the psoriasis
xenograft transplantation model partially by controlling
proliferation and by inducing apoptosis.
It would be interesting to further investigate whether
valrubicin also has an effect on proliferation and self-renewal
of the infiltrating lymphocytes present within the
psoriatic plaque. Indeed, some anthracyclines have been
described to have an anti-inflammatory effect (Olson et al.,
2007).
Moreover, it would be of interest to study whether
valrubicin has a therapeutic effect on other types of skin
disease as well, in which cellular hyperproliferation and
tissue inflammation are involved.
MATERIALS AND METHODS
Donors and keratome skin biopsies
Psoriatic plaque keratome skin biopsies were obtained from three
donors with moderate-to-severe plaque psoriasis aged 41–65 years
(mean: 56±13). The psoriatic patients were untreated for at least 1
month before biopsy and informed consent was obtained. The study
was approved by the Central Ethical Committee and conducted in
accordance with the Declaration of Helsinki protocols.
Xenograft transplantation
Each keratome skin biopsy (17 5 0.05 cm, containing both
epidermis and dermis) from the three donors was split into 12 grafts
and transplanted onto C.B-17 SCID mice, 6- to 8-week olds (Taconic
M&B, Silkeborg, Denmark), as described (Dam et al., 1999). Shortly
thereafter, the mice were anesthetized before surgery by a
subcutaneous injection of Ketaminol (ketamine, 100mg kg1;
Intervet, Skovlunde, Denmark) and Narcoxyl (xylazine, 10mg kg1;
Intervet). The back was shaved and part of the exposed skin was
removed. The grafts were sutured with an absorbable 6-0 suture
(Caprosyn, Tyco, Copenhagen, Denmark) and covered with Xero-
form dressings (Sherwood Medical Company, Markham, ON,
Canada) for 1 week. The mice were kept under pathogen-free
conditions throughout the study. Psoriatic plaque grafts healed for 10
days before the mice were divided randomly into four groups. Three
groups were treated topically once daily for 12 days with either
valrubicin (0.01 gml1) or vehicle (creams generously provided by
Valderm ApS, Lyngby, Denmark), or with clobetasol propionate
(Dermovat, GlaxoSmithKline, Middlesex, UK). The last group was
left untreated. After treatment, retro-orbital blood samples were taken
and analyzed for the presence of valrubicin and its metabolites by
liquid chromatography-tandem mass spectrometry (detection limit
1 ngml1). Animal studies were carried out with permission from the
Danish Experimental Animal Inspectorate.
Xenograft evaluation
The severity of psoriatic lesions in the grafts was assessed twice
weekly in a blinded manner and was scored semiquantitatively
according to the following clinical signs: scaliness, induration, and
erythema. The parameters were scored using a 3-point scale:
0¼ complete lack of cutaneous involvement; 1¼ slight involvement;
2¼moderate involvement; and 3¼ severe involvement. On this
scale from 0 to 3, a maximal score of 3 represented severe scale,
induration, and erythema of the psoriatic xenografts, as described
(Dam et al., 1999; Stenderup et al., 2009).
After treatment, biopsies from the center of the graft were
obtained and embedded in paraffin. Using standard methods, biopsy
sections were stained histochemically with hematoxylin/eosin.
Epidermal thickness, an accepted end point for measuring psoriasis
severity, was measured on three equally distant cut sections (average
of 20 random measurements from the stratum corneum to the
deepest part of the rete pegs). All sections were blinded before
evaluation and were evaluated randomly.
Penetration study
Penetration of valrubicin, AD41, and doxorubicin into keratinocytes
in vitro was assessed by growing HaCaT cells in standard conditions
(37 1C and 90% humidity) in Dulbecco’s modified Eagle’s medium
(Gibco, Paisley, UK), with 10% fetal bovine serum (Gibco) added
to penicillin, streptomycin, and gentamicin (Bie & Berntsen, Aarhus,
Denmark). HaCaT cells at a concentration of 13,000/cm2 were seeded
on Permanox chamber slides (Nunc, Roskilde, Denmark) overnight
before exposure to valrubicin (1mgml1), AD41 (10mgml1), and
doxorubicin (0.5mgml1) for 10minutes, 30minutes, 2 hours, and
4hours. Cells were then fixed by air-drying and were mounted with
ProLong Gold antifade reagent with DAPI (Invitrogen, Eugene, OR).
As these compounds are auto-fluorescent (Kanter and Schwartz,
1979), it was possible to detect the intracellular localization by
confocal microscopy using a Leica DMRXE vertical microscope
(Leica, Wetzlar, Germany) and the Leica TCS SL laser confocal
system. The excitation wavelength was set at 488 nm and emission
was registered in the interval of 530–590 nm.
Proliferation in vitro and in vivo
Proliferation of HaCaT cells and primary keratinocytes from three
healthy donors in the presence of valrubicin, AD41, or doxorubicin at
increasing doses (0.01, 0.05 0.1, 0.5, 1, and 5mgml1) was assessed as
a measure of luminescence produced using the CellTiter-Glo viability
assay kit (Promega, Nacka, Sweden) after 24, 48, and 72hours from
exposure. Cells were seeded at a concentration of 2,000 (6,500/cm2)
and 4,000 (13,000/cm2) for HaCaT cells, and at 4,000 (13,000/cm2)
for primary keratinocytes, per well in a 96-well plate in quadrupli-
cate and were treated the next day. The effect on proliferation was
evaluated as a percentage of reduction in viability.
In vivo, biopsy sections were stained using standard immuno-
histochemical methods for K16 (Abcam, Cambridge, UK). K16
expression was detected using the Alexa Fluor 488 Goat Anti-Rabbit
SFX Kit (Invitrogen) and ProLong Gold antifade reagent with DAPI
(Invitrogen). We used normal rabbit IgG (Santa Cruz Biotechnology,
Heidelberg, Germany) as isotype control.
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Apoptosis
Apoptosis induced by valrubicin, AD41, and doxorubicin was observed
by staining HaCaT cells grown on Permanox chamber slides (Nunc)
using Alexa Fluor 488-conjugated annexin V (Vybrant Apoptosis Assay
Kit #1–Alexa Fluor 488 annexin V/SYTOX Green, Invitrogen), which
recognizes phosphatidylserine molecules. HaCaT cells (13,000/cm2)
were exposed for 10 and 30minutes to valrubicin (0.1mgml1),
AD41 (1mgml1), doxorubicin (0.05mgml1), and to medium alone.
Apoptotic cells were visualized by fluorescent microscopy.
An evaluation of intrinsic apoptosis was carried out by seeding
HaCaT cells in a 96-well plate, as carried out for the proliferation
study, and incubating overnight before exposure to valrubicin (0.05
and 0.1 mgml1), AD41 (0.5 and 1mgml1), and doxorubicin (0.05
and 0.1 mgml1). At 24 and 48 hours, initiator and effector markers
of apoptosis were assessed in the form of activation of caspase 9
and caspases 3 and 7, respectively, by measuring the luminescence
produced following the protocol by the Caspase CellTiter-Glo
apoptosis assay kit (Promega).
In vivo apoptosis was assessed by staining sections from biopsies
of valrubicin- and vehicle-treated grafts for the caspase cleavage
product of cytokeratin 18 with the M30 CytoDEATH antibody
(Roche Applied Science, Mannheim, Germany). Detection was
achieved using sheep anti-mouse Ig biotinylated antibody (Millipore,
Copenhagen, Denmark), followed by streptavidin-HRP (Vector
Laboratories, Peterborough, UK) and DAB chromogen (Dako,
Glostrup, Denmark), following the manufacturer’s protocol.
Statistics
The nonparametric Kruskal–Wallis test was used to test for
differences between treatment groups in semiquantitative clinical
psoriasis scores. Student’s t-test was used to test the null hypothesis
of no difference between treatment groups for epidermal thickness.
The analysis was adjusted for patients (as each patient’s skin was
donated to several mice) and mice (as several observations were
made for each mouse). Observations made on the same mouse were
assumed to be correlated. Observations made for different mice
were assumed to be independent of each other. All tests were two-
sided and P-values o0.05 were considered as significant.
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